Disease relevance of Pidotomod

• Activity of the new immunostimulant PGT/1A against experimental bacterial infections [1].
• The efficacy and safety of pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl)carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) were rated in a child population with a remote history of recurrent respiratory infections (RRI) [2].
• The pharmacokinetics of pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl) carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) in elderly volunteers and in patients with renal failures were investigated [3].
• The aim of this study was to evaluate the activity of pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl)carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) on 52 patients affected with chronic obstructive pulmonary disease (COPD) [4].

High impact information on Pidotomod

• Pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl)carbonyl]-thiazolidine- 4-carboxylic acid, PGT/1A, CAS 121808-62-6) is a new synthetic immunostimulant, which has proved to possess a high activity [5].
• (R)-3-[(S)-(5-Oxo-2-pyrrolidinyl)carbonyl]-thiazolidine-4-carboxylic acid (Ib, Pidotimod, PGT/1A, CAS 121808-62-6) was selected for further research [6].
• The efficacy and safety of a new synthetic immunostimulant pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl) carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) in recurrent infections of the primary airways were assessed in a group of 416 children with a history of recurrent respiratory infections (RRI) [7].
• Experiments were performed to analyze the effect of the immunomodulating agent pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl) carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) on the mouse splenic proliferative response to Con-A and IL-2, natural killer (NK) cell activity and thymocyte apoptosis [8].
• Activity of PGT/1A, a new immunostimulating drug, on macrophages and lymphocytes in immunodepressed mice [9].

Biological context of Pidotomod

• The mutagenic potential of pidotimod ((R)-3-[(S)-(5-oxo-2- pyrrolidinyl)carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) was assessed in a series of five assays designed to measure gene mutation, chromosomal damage and primary DNA damage [10].

Associations of Pidotomod with other chemical compounds

• This paper describes a HPLC method for the determination of Pidotimod (3-L-pyroglutamyl-L-thiazolidine-4-carboxylic acid; PGT/1A), a new biological response modifier, in plasma [11].

References